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Loss-of-function (LOF) mutations in ANGPTL3, an inhibitor of lipoprotein lipase (LPL), 
cause a drastic reduction of serum lipoproteins and protect against the development of 
atherosclerotic cardiovascular disease. Therefore, ANGPTL3 is a promising therapy target. 
We characterized the impacts of ANGPTL3 depletion on the immortalized human 
hepatocyte (IHH) transcriptome, lipidome and human plasma lipoprotein lipidome. The 
transcriptome of ANGPTL3 knock-down (KD) cells showed altered expression of several 
pathways related to lipid metabolism. Accordingly, ANGPTL3 depleted IHH displayed 
changes in cellular overall fatty acid (FA) composition and in the lipid species composition 
of several lipid classes, characterized by abundant n-6 and n-3 polyunsaturated FAs 
(PUFAs). This PUFA increase coincided with an elevation of lipid mediators, among which 
there were species relevant for resolution of inflammation, protection from lipotoxic and 
hypoxia-induced ER stress, hepatic steatosis and insulin resistance or for the recovery 
from cardiovascular events. Cholesterol esters were markedly reduced in ANGPTL3 KD 
IHH, coinciding with suppression of the SOAT1 mRNA and protein. ANGPTL3 LOF caused 
alterations in plasma lipoprotein FA and lipid species composition. All lipoprotein fractions 
of the ANGPTL3 LOF subjects displayed a marked drop of 18:2n-6, while several highly 
unsaturated triacylglycerol (TAG) species were enriched. The present work reveals distinct 
impacts of ANGPTL3 depletion on the hepatocellular lipidome, transcriptome and lipid 
mediators, as well as on the lipidome of lipoproteins isolated from plasma of ANGPTL3-
deficient human subjects. It is important to consider these lipidomics and transcriptomics 
findings when targeting ANGPTL3 for therapy and translating it to the human context. 
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Cardiovascular diseases (CVD) are one of the leading causes of death worldwide [1]. 
Dyslipidemia, mainly elevated low-density-lipoprotein (LDL) cholesterol and triglyceride 
rich lipoproteins (TRLs), is the major risk factor for the development of CVD. Statins and 
ezetimibe, which reduce LDL-cholesterol, are used as the most common standard 
therapeutics for CVD treatment [2]. However due to a high level of residual CVD risk 
refractory to these therapies, efforts have been made to identify novel targets and 
treatment modalities for CVD [3]. Angiopoietin like protein 3 (ANGPTL3) is one of the main 
targets in this line of research. Among the ANGPTL family of proteins ANGPTL3, 4 and 8, 
play crucial roles in lipoprotein metabolism. They are potent inhibitors of LPL, which 
hydrolyzes triglyceride rich lipoproteins (TRLs) [4;5]. Loss of function (LOF) mutations of 
the ANGPTL3 gene were initially found in human subjects with extremely low serum 
triglycerides [6] and were later found to confer protection from coronary artery disease [7]. 
The ANGPTL3 LOF variant carriers exhibit hypolipidemia and high insulin sensitivity [8;9]. 
They have low levels of all major plasma lipoprotein classes (VLDL, LDL and HDL) [8;9]. 
Accordingly, this disorder was designated as a familial combined hypolipidemia (FHBL2; 
OMIM #605019) [6;8]. Moreover, plasma free fatty acid (free FA) level is reduced in the 
ANGPTL3 LOF carriers [9]. ANGPTL3 LOF variant carriers are not known to exhibit any 
adverse health effects and they seem to display an increased life expectancy [10;11]. 
ANGPTL3 deficient subjects have been reported to lack significant coronary 
atherosclerotic plaques and also heterozygous ANGPTL3 LOF variant carriers display 35-
40% attenuated risk of CAD compared with the general population [7;12]. ANGPTL3 has 
therefore emerged as a potential therapeutic target for cardiovascular disorders. A human 
monoclonal antibody against ANGPTL3, REGN1500, was shown to lower plasma lipids in 












antibody Evinacumab exhibited hypolipidemia [12]. Similar results were obtained in both 
humans and mice when ANGPTL3 was silenced using an antisense-oligonucleotide 
approach [14].  
ANGPTL3 is a protein secreted by hepatocytes [15], and insulin downregulates its 
expression in liver and plasma [16]. Of note, ANGPTL3 acts as an inhibitor of both LPL 
and endothelial lipase (EL) [17;18]. Inactivation or suppression of ANGPTL3 reduces 
plasma lipids by enhancing LPL activity, reducing hepatic VLDL-triglyceride secretion and 
enhancing LDL/VLDL uptake by the liver [19;20]. The enhancement of EL activity upon 
ANGPTL3 inhibition may explain the reduction of HDL observed in ANGPTL3 LOF carriers 
[18]. ANGPTL3 was also reported to induce adipocyte lipolysis [21], which provides a 
putative explanation for the reduction of FAs in the plasma of the LOF carriers [9].  
 
Even though the functions of ANGPTL3 in the circulation are relatively well characterized, 
many mechanistic questions regarding the molecular consequences of ANGPTL3 LOF 
and protection against CVD remain unanswered. Although recent metabolic signature of 
lipoprotein classes from ANGPTL3 deficient subjects based on NMR [22] introduced some 
novel observations, the detailed lipid composition of the plasma lipoproteins of these 
subjects and how it may be linked to CVD protection are unclear. Likewise, the intracellular 
role of ANGPTL3 as a regulator of the hepatic lipid composition and function have not 
been studied in detail. To aid in understanding the molecular mechanisms exerted by 
ANGPTL3 deficiency, we addressed the alterations of hepatocellular and plasma lipid 















2 Material and Methods 
  
2.1 Cell culture and generation of immortalized human hepatocytes (IHHs) with 
ANGPTL3 stably knocked down  
IHHs immortalized by SV40 large T-Antigen (IHH, ATCC® PTA-5565TM) were cultured in 
Williams E medium (Gibco by Life Technologies, 22551-022) with added 10%(v/v) fetal 
bovine serum (FBS), 0.2 mg/ml glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin. 
The cells were transduced with MISSIONTM shRNA (short hairpin RNA) Lentiviral Vector 
particles (TRCN0000242782, Sigma Aldrich) targeting ANGPTL3 (NM_014495.2), 
validated in Tikka et al. [23], or with a non-targeting shRNA (SHCOO2, Sigma Aldrich) 
[MOI (multiplicity of infection) 1]. Transduced cells were selected with 5 μg/ml puromycin 
and cultured further in the above medium containing puromycin.  
 
2.2 Gene expression analysis (qPCR) 
Expression of ANGPTL3 and SOAT1 genes were analyzed by quantitative polymerase 
chain reaction (qPCR). Total RNA was extracted from the ANGPTL3 KD and control IHH 
cells using PureLink® RNA Mini Kit according to the manufacturer’s protocol. cDNA 
synthesis was carried out using SuperScript® VILOTM reverse transcriptase kit (Invitrogen, 
11754050). Quantitative real time PCR was performed with gene-specific primers 
(Supplementary table 1) and LightCycler® 480 SYBR Green I Master mix (Roche, 
04707516001) using Light Cycler 480 II instrument (Roche Applied Science, Penzberg, 
Germany). β-actin and RPLP0 (Large Ribosomal Protein) were used as housekeeping 













2.3 Western blotting 
ANGPTL3 silenced IHH hepatocytes and control cells were lysed in RIPA buffer (15 mM 
Tris-HCl, pH7.4, 1.25% sodium deoxycholate, 1% NP40, 1% SDS, 1 mM EDTA, 150 mM 
NaCl). Proteins were resolved on 12 % sodium dodecyl sulfate polyacrylamide gels and 
blotted onto PVDF membrane using BioRad transblot system. Blots were probed with anti-
ANGPTL3 (R332), an antibody developed in New Zealand White rabbits against a peptide 
EDQYKQLNQQHSQIKEIENQ of human ANGPTL3, or anti-SOAT1 (Santa Cruz sc-
69836), in Tris buffered saline containing 5% bovine serum albumin and 0.1% Tween 20. 
Enhanced chemiluminescence reagent (BioRad Clarity Max™ or Thermo Scientific, 
Waltham, MA) was used to develop and BioRad Chemidoc imaging system was used to 
capture the signals. Protein bands were normalized to the total protein content of the 
corresponding lane using Image Lab software (BioRad). 
 
2.4 Next generation RNA sequencing 
IHH cells were cultured on 6-well plates (n=4) in the conditions specified above for 48 h, 
after which they were changed into fresh growth medium without puromycin and incubated 
for 4 h. RNA was extracted from the ANGPTL3 KD and control IHH cells using RNeasy® 
Mini Kit (Qiagen, 74104) according to manufacturer’s protocol. 
NEBNext Ultra Directional RNA Library Prep Kit for Illumina was used to generate cDNA 
libraries for next generation sequencing. The mRNA was purified using magnetic beads 
and then fragmented in order to generate inserts of approximately 200 bp, and primed with 
random primers. The first strand cDNA synthesis utilized Actinomycin D, which inhibits the 
DNA polymerase activity of the reverse transcriptase increasing strand specificity. In the 












the second strand with uracils (U). The cDNA synthesis product was purified with 
Agencourt AMPure XP beads. Next, the cDNA was end-repaired, and adapter ligated 
utilizing dA-tailing. The adaptor ligated DNA went through a bead-based size selection 
after which the final PCR enrichment took place. Each sample was given a unique index to 
enable pooling of multiple samples (multiplexing) for sequencing. During the high-fidelity 
PCR, USER (Uracil-specific Excision Reagent) enzyme cut away the uracil strand 
preserving only the first strand. In addition, the loop adaptor was cut open to enable the 
PCR. The amplified library was then purified using AMPure XP Beads. Library quality was 
assessed by Bioanalyzer (Agilent DNA High Sensitivity chip) and library quantity by Qubit 
(Invitrogen). Sequencing was performed with Illumina NextSeq system, High Output 75 
cycles kit.  
STAR 2.5.1b (PMID: 23104886) was used for aligning output sequencing data to human 
reference genome (GRCh38) and “featureCounts” program from the Subread 1.5.0 
(PMID:24227677) to count uniquely mapped fragment against genomic features defined 
by the GENCODE annotation file (Homo_sapiens.GRCh38.89.gtf). Differential gene 
expression (PMID: 25516281) was analyzed with Deseq2 1.22.1 and Benjamini–Hochberg 
method was used to control for false discovery rate. The transcripts with no counts in all 
samples were removed. Ensembl version 98 was used for gene annotation.  
Gene set enrichment analysis and gene set over-representation analysis were performed 
using the clusterProfiler R package [24]. Overrepresentation analysis was performed using 
all genes, which had an adjusted p-value < 0.05 (Benjamini–Hochberg). Network graphs 














2.5 Study participants and lipoprotein isolation from human plasma 
The clinical characteristics of the study participants are summarized in Supplementary 
table 2. The study protocol was approved by the Ethical Committee of Sapienza University 
of Rome, and informed consent was obtained from all the study participants. ANGPTL3 
LOF homozygotes and controls were matched for age, sex and BMI. The participants 
selected for this study are a subpopulation of a larger cohort described in previous studies 
[22;27]; The groups have been reported to have comparable dietary intake, physical 
activity, smoking prevalence, and use of anti-inflammatory medications. 
Lipoprotein fractions (VLDL, LDL and HDL) were isolated from plasma by sequential 
density ultracentrifugation as described previously [28]. 
 
2.6 Lipidomics of IHH cells and lipoprotein fractions by ESI-MS/MS and gas 
chromatography (GC) 
For IHH lipidomics, ANGPTL3 KD and control IHH cells were first cultured on 6-well (n=6) 
plates for 48 h as mentioned above. Fresh medium without puromycin was changed into 
the wells and cells were incubated for 24 h, washed with ice-cold PBS and finally scraped 
into 1 ml of ice-cold 0.25 M sucrose. An aliquot of 100 μl was taken from each sample for 
total protein analysis using BCA assay (Thermo Fisher Scientific, 23227). The samples 
were stored in -80°C for 7 weeks before lipid extraction. 
Lipids of IHH cell samples and lipoprotein fractions were extracted according to Folch at al. 
[29]. Solvents were evaporated and the lipid extracts immediately dissolved in 
chloroform/methanol 1:2 (by vol) and right before mass spectrometry 1% NH4OH was 
added together with SPLASH® LIPIDOMIX® Mass Spec Standard (Avanti Polar Lipids, 












mass spectrometer (Agilent 6490 Triple Quad LC/MS with iFunnel Technology; Agilent 
Technologies, Santa Clara, CA) and their lipids species were identified and quantified 
using lipid class specific detection modes, as previously described [30]. Retrieved spectra 
were processed by MassHunter Workstation qualitative analysis software (Agilent 
Technologies, Inc.), and individual lipid species were quantified using the internal 
standards and LIMSA software [31]. 
An aliquot of the lipid extracts were used for determining the FA composition of total lipids 
of the samples by GC according to the principles described in Käkelä et al. [32]. The 
extracted lipids were transmethylated by heating with 1% H2SO4 in methanol under 
nitrogen atmosphere, and the formed FA methyl este s  (FAME) extracted twice with 
hexane, dried with anhydrous Na2SO4 and concentrated. The FA structures were identified 
using GCMS-QP2010 Ultra (Shimadzu Scientific Instruments, Kyoto, Japan) with mass 
selective detector (MSD) and the FA proportions quantified using Shimadzu GC-2010 Plus 
equipment with flame-ionization detector (FID). Both instruments were equipped with 
Zebron ZB-wax capillary columns (30 m, 0.25 mm ID and film thickness 0.25 μm; 
Phenomenex, Torrence CA, USA).  
 
2.7 Metabolic labeling of cholesterol ester 
Control IHH and ANGPTL3 KD cells were grown on 6-well plates to confluency. Cells were 
then incubated with [3H]acetic acid (50 μCi/well; Perkin Elmer, NET003025MC) in medium 
without puromycin for 3 h, washed with cold PBS and scraped into cold 2% NaCl. Total 
lipids were extracted according to Bligh and Dyer [33]. The lipid classes of the samples 
were separated by thin layer chromatography on silica gels and hexane/diethyl 












along with the samples, and lipid spots were stained with iodine vapor. CE bands were 
scraped and their [3H]radioactivity was measured by liquid scintillation counting, and the 
results normalized for total cell protein. Additionally, [3H]oleic acid labeling (2.5 μCi/well; 
Perkin Elmer, NET289005MC) was carried out as described above for [3H]acetic acid.  
 
2.8 Lipid mediator analysis 
Control IHH and ANGPTL3 KD cells were cultured for 48 h on 6-well plates (n=3) in 
complete Williams E medium with puromycin after which the medium was changed to 
William’s E medium (Gibco, A1217601, no phenol red) with added 10% (v/v) FBS, 0.2 
mg/ml glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin. After 24 h incubation the 
medium was changed to one containing 1 % FBS. After 1 h the plates were frozen and 
stored in -80°C before analysis. Also a control sample without cells was prepared 
simultaneously using the same conditions. 
Subsequently, two volumes of cold MeOH containing deuterium-labelled synthetic d4-
PGE2, d8-5-HETE, d4-LTB4, d5-LXA4, d5-RvD2, d5-LTC4, d5-LTD4, d5-LTE4 (500 pg each), 
d5-MaR1, d5-MaR2, d5-RvD3 (250 pg each), d5-RvE1(100 pg), and d5-17R-RvD1 (25 pg) 
were added onto the wells. Cells were lifted and transferred together with the supernatant. 
These were then stored at −20 °C for at least 45 min and then centrifuged at 2500 rpm for 
10 min. Supernatant was collected and concentrated to ~1.0 ml using a gentle stream of 
nitrogen gas (TurboVap LV system, Biotage). Solid phase extraction (SPE) was then 
performed through ExtraHera automated extraction system (Biotage) adding 9 ml of 
aqueous pH 3.5 HCl solution. The acidified samples were then loaded onto conditioned 
C18 500 mg 200-0050-B cartridges (Biotage). Samples were washed with 4.0 ml of H2O 












evaporated using a gentle stream of nitrogen (TurboVap LV, Biotage) and samples re-
suspended in 40 μl of MeOH:H2O (1:1, vol/vol) solution. Samples were centrifuged at 2500 
rpm for 5 min and the supernatant centrifuged again at 9900 rpm for 10 s, 4 °C [34].  
LC-MS-MS profiling was performed as described previously [34]. Following C18 SPE and 
concentration, samples were analyzed using QTrap 6500+ (ABSciex) MS system, coupled 
with a Shimadzu SIL-20AC HT auto sampler, and LC-20AD LC pumps. Agilent C18 
Poroshell column (150 mm × 4.6 mm × 2.7 μm) was used to separate lipid mediators. 
Using a constant flow rate of 0.5 ml/min, eluents gradient started at 20:80:0.01 (vol/vol/vol) 
in MeOH/H2O/acetic acid for 0.2 min that was ramped to 50:50:0.01 (vol/vol/vol) over 12 s, 
maintained for 2 min, ramped to 80:20:0.01 (vol/vol/vol) over 9 min and maintained for 3.5 
min, then ramped to 98:2:0.01 (vol/vol/vol) and maintained for 5.5 min. Mediators were 
identified by matching retention time to synthetic and authentic materials using a MRM 
developed with signature parent ion and characteristic daughter ions coupled with an 
Enhanced Product Ion (EPI) for matching mass spectra. Quantification was obtained 
through calibration curves from synthetic or authentic compounds and deuterium-labeled 
lipid mediators.  
 
2.9 Statistical analysis 
For univariate comparisons statistical differences were tested using a two-tailed Student’s 
t-test. Principal Component Analysis (PCA) (Sirius, PRS, Bergen, Norway) was applied for 
multivariate comparisons of detailed lipid profiles. PCA reveals compositional differences 
between the samples, and also shows the lipid species mainly responsible for the variation 
in the data. Data used for the PCA were arcsine transformed to improve data normality 












the first two principal components. The differences between the groups seen in the PCA 
were further quantitatively analyzed using Soft Independent Modeling of Class Analogy 
(SIMCA; Sirius) [35].  For lipid mediator statistics multivariate Partial Least Square 
Discriminant Analysis (PLS-DA) was performed by means of the software SIMCA 
(Umetrics), building a model with R2X=1, R2Y=1, and Q2=1. Variable Importance in 
Projection (VIP) score was used to highlight the most important lipid mediators 
discriminating the two groups. 
 
 
3 RESULTS AND DISCUSSION 
 
3.1 Several genetic pathways related to lipid metabolism are altered in ANGPTL3 
knock-down hepatocytes 
ANGPTL3 KD hepatocytes (IHH) were created using an shRNA lentiviral vector. An 
approximately 90% KD efficiency was observed at mRNA level when compared to control 
cells transduced with non-targeting shRNA (Figure 1A), and the KD effect was evident 
also at the protein level (Figure 1 B and C). KEGG pathway analysis of the next 
generation RNA sequencing (RNAseq) data of the ANGPTL3 KD and control IHH cells 
revealed that several pathways related to lipid metabolism are affected upon the knock-
down (Table 1). Similarly, when Reactome pathway analysis was performed using only the 
statistically significantly up/downregulated genes, all of the ten most affected pathways in 
the ANGPTL3 KD cells were related to lipid and FA metabolism (Supplementary Figure 
1). Thus we chose to study the cells further using lipidomics approaches to address 












When looking at the other pathways significantly affected in the KEGG enrichment 
analysis, two pathways related to longevity emerged and were among the 50 most altered 
pathways: Longevity regulating pathway - multiple species, and Longevity regulating 
pathway (Supplementary table 3). This is an interesting and relevant observation when 
considering that subjects homozygous for LOF variants of ANGPTL3 reach older age than 
the average population [11]. The Campodimele region, where the ANGPTL3 loss-of-
function mutations are found enriched, is known for the longevity of its residents, with the 
town's population now expected to live to an average age of 95 [10;36]. Moreover, insulin 
sensitivity is increased in the ANGPTL3 LOF subjects [9]. According to the present KEGG 
enrichment analysis, also pathways related to insulin resistance/sensitivity, signaling and 
secretion are altered in the ANGPTL3 KD cells. In a revious study by Tikka et al. [23], it 
was reported that the KD of ANGPTL3 in IHH improves glucose uptake and that during 
insulin stimulation the cells secrete TAG-poor VLDL instead of TAG-enriched large VLDL 
particles. They concluded that silencing of ANGPTL3 improves insulin sensitivity of the 
IHH and suggested a liver-specific mechanism to be involved in the insulin-sensitive 
phenotype of ANGPTL3 LOF subjects. The present RNAseq observations support this 
notion. 
 
3.2 The ANGPTL3 knock-down cells are enriched in n-3 and n-6 polyunsaturated and 
depleted in monounsaturated fatty acids 
As the first lipidomic approach we determined the total FA profile of ANGPTL3 KD and 
control IHHs by GC. The reported profile represents FAs derived from all lipid species of 
the cell and the results are presented as molar percentages (Supplementary table 4). In 
ANGPTL3 KD cells the sum of monounsaturated FAs (MUFAs) was significantly 












increased when compared to controls (Figure 2A). However, there was no difference in 
the n-3/n-6 FA ratio or the unsaturated/saturated FA ratio between control and ANGPTL3 
KD cells. When the FA data were subjected to principal component analysis (PCA) 
(Figure 2B), the difference between control and ANGPTL3 KD cell groups reached the 
statistical significance when tested with SIMCA (p<0.05). The groups separated from each 
other in the direction of principal component 2 (PC 2), which explained 25.3% of the total 
variation. The FAs influencing PC2 the most were 20:5n-3 (eicosapentaenoic acid, EPA) 
and 20:4n-6 (arachidonic acid, AA) furthest from the origin in the upward direction, and 
relatively enriched in the ANGPTL3 KD cells, and 20:3n-9 (eicosatrienoic acid) furthest 
from the origin in the downward direction, and enriched in the controls. EPA and AA can 
be produced from essential FAs 18:3n-3 (α-linolenic acid) and 18:2n-6 (linoleic acid) via 
desaturation/elongation processes, respectively, or taken up from the culture medium. FA 
20:3n-9 is considered a marker of essential fatty acid deficiency: It is a PUFA synthesized 
from the non-essential 18:1n-9 (oleic acid) [37]. Of note, we observed in the RNAseq an 
upregulation of CD36, FABP3, FABP5 and FABP6 mRNAs in the ANGPTL3 KD cells. 
Since FABP3, -5 and -6 facilitate the cellular uptake of long chain FAs and PUFAs [38-41], 
we consider it possible that the uptake of FAs and especially PUFAs from the culture 
medium is enhanced in the ANGPTL3 KD cells. 
We next analyzed the IHH lipids at the class level (Supplementary tables 5-8) by mass 
spectrometry. There were no differences between the control and ANGPTL3 KD cells in 
the concentrations of the major phospholipid classes PC, PE and PI when normalized to 
total cellular protein (data not shown). PCA of lipid species profiles in these classes of 
lipids showed similar separation between control and ANGPTL3 KD cells largely driven by 
MUFA- (relative reduction in the KD cells) and PUFA- (enrichment in the KD cells) 












released from glycerophospholipids through the action of phospholipases such as 
cytosolic PLA2 (cPLA2) [42;43], two isoforms of which, PLA2G4A and PLA2G4C, are 
upregulated in our RNAseq data. Cytosolic PLA2 shows specificity for PUFAs, especially 
for 20:4n-6, 22:6n-3 (docosahexaenoic acid, DHA) and 20:5n-3 [42;43], and plays an 
important role in the initiation of cellular signaling, hydrolyzing the ester bond at the sn-2 
position of glycerophospholipids. Thereby the released PUFAs can be used for the 
synthesis of bioactive lipid mediators [44]. Phosphatidylinositol (PI) is considered a major 
source of 20:4n-6 released by cPLA2 since 20:4n-6 is the most abundant PUFA in this PL 
class, the largest PI component being the 20:4n-6-containing species 38:4 (m/z 885  
[45;46]. Indeed, in the PCA of our data PI 38:4 was the variable responsible for the largest 
part of the data variation on PC1 in the leftward direction, and the high level of PI38:4 
separated ANGPTL3 KD samples from the control cells. Similarily, the PI 38:5 (likely a 
mixture of FAs 20:4, 22:5, 20:5 in the sn-2 position) was a characteristic of the ANGPTL3 
KD cells.  
Interestingly, it has been established that the relative FA compositions of the PI-derived 
signaling mediators phosphatidylinositol-phosphates (PIPs) reflect that of PI [47] and that 
polyunsaturated diacylglycerol (DAG) species derived from PI(4,5)P2 can activate the PKC 
α, ε, and δ isoforms [46]. This may also in part explain why the PIP signaling KEGG 
pathways are significantly affected in the present transcriptomics data (Table 1): The 
increase of PUFAs in the ANGPTL3 KD cells may through this mechanism impact PIP2 
signaling. Closer examination of the KEGG phosphatidylinositol signaling pathway 
(Supplementary Figure 3) shows that several of its genes are upregulated in the KD 
cells, but phospholipase C (PLC), a key component in the pathway, is strongly 
downregulated. This could represent an allostatic mechanism aimed at maintaining a 












3.3 Knocking down ANGPTL3 changes the lipid mediator profile of hepatocytes  
Prompted by analyses showing changes in several KEGG pathways related to FA and 
glycerophospholipid metabolism as well as the increase of PUFAs in the ANGPTL3 KD 
cells, we decided to explore the bioactive PUFA-derived lipid mediators produced by the 
cells (Supplementary table 9). The results shown represent the sum of intracellular and 
secreted lipid mediators since both the cells and the medium were analyzed as one 
sample. There was a clear trend towards an increase of lipid mediators in the ANGPTL3 
KD cells, and PLS-DA analysis separated the ANGPTL3 KD and control samples (Figure 
3A). Figure 3B displays VIP scores of the 15 most important lipid mediators affecting 
separation of the groups in the PLS-DA analysis. The mediator with the highest VIP score 
was RvD6, an important specialized pro-resolving mediator (SPM) with a suggested role in 
coronary artery disease (CAD). RvD6 was shown to be elevated in CAD patients receiving 
n-3 FA supplement and it promoted macrophage uptake of blood clots in vitro [48]. 
Maresin 2 (MaR2) and 22-OH-MaR1, which also showed high VIP scores, are SPMs 
characterized in macrophages [49] and neutrophils [50], respectively. Of note MaR1, the 
precursor to 22-OH-MaR1, protects hepatocytes from lipotoxic and hypoxia-induced ER 
stress [51] suggesting that 22-OH-MaR1 may display similar biological actions given that 
this further metabolite retains the potent biological actions of its parent SPM [50]. The 
protectin pathway products from both n-3 docosapentaenoic acid (DPA) and DHA, i.e. 
10S,17S-diHDPA and 10S,17S-diHDHA (protectin DX), were also increased in ANGPTL3 
KD cells. PDX prevents lipid-induced ER stress, thereby ameliorating hepatic steatosis 
and hepatic insulin resistance [52;53]. Another mediator with a high VIP score, 15-epi-
LXA4 is reported to down-regulate pro-inflammatory eicosanoids and potentiate the 












Prostaglandins (PG) PGD2, PGF2a and PGE2 all had a high VIP score in the present data. 
They are generally referred to as pro-inflammatory mediators [56], but especially PGE2 is 
also important for the lipid mediator class switching at the beginning of the resolution 
phase as it decreases the production of pro-inflammatory leukotriene B4 (LTB4) species 
[57]. The increased production of lipid mediators in the ANGPTL3 KD cells is consistent 
with the findings of Holopainen et al. [58], who concluded that elevated amounts of PUFAs 
(AA, EPA and DHA) in membrane phospholipids lead to increased production of lipid 
mediators. Increased substrate availability, PLA2 upregulation, and also the substrate 
preference of PLA2 towards PUFA- containing phospholipids [42;43] provide plausible 
explanations for the observed increase of PUFA-derived lipid mediators in the ANGPTL3 
KD cells.  
 
3.4 Cholesterol ester synthesis is reduced in ANGPTL3 KD cells 
In addition to elucidating the effects of ANGPTL3 KD on phospholipid and FA metabolism, 
we also investigated cholesterol metabolism by multiple approaches. First, we looked at 
the profile (Supplementary table 8) and total level (Figure 4A) of cholesterol esters (CEs) 
in the IHH by using ESI-MS/MS. The relative CE species profile of the ANGPLT3 KD cells 
showed similar alterations in the MUFA and PUFA-containing species as described for 
total cellular FAs and phospholipids (Figure 2; Supplementary tables 4-7). The level of 
the major CE species 18:1 was significantly (p<0.001) reduced and that of the second 
largest component, the DHA-containing CE 22:6n-3, increased by 74%. The latter finding 
appears as a class-specific change since DHA was not increased but rather decreased in 
the total IHH FA profile, driven by altered FA composition of glycerophospholipids. The 
total level of CE was significantly (p<0.001) decreased in the ANGPTL3 KD cells when 












encoding ACAT1, an enzyme synthesizing CEs [59], was decreased in the KD cells both 
at the mRNA (Figure 4B) and protein (Figure 4C-D) levels. Accordingly, we next 
investigated CE synthesis and FA incorporation into CEs in the IHH by [3H]acetic acid and 
[3H]oleic acid labeling, respectively, and also analyzed the synthesized unesterified 
cholesterol in the [3H]acetic acid labeled samples. With both radioisotope precursors the 
level of labeled CEs was significantly (p<0.001) reduced in the ANGPTL3 KD cells (Figure 
4E-F), without a change in the labeling of unesterified cholesterol in cells treated with 
[3H]acetic acid (data not shown). Thus, knocking down ANGPTL3 in IHH significantly 
reduces the esterification of cholesterol. The reduction of CEs putatively mediated by 
suppression of ACAT1 function might affect the packaging of CEs to nascent VLDL and 
thereby their secretion. In agreement with these data we previously reported that there 
was a reduction of CE/apoB ratio in plasma VLDL and LDL particles derived from 
ANGPTL3 LOF homozygote carriers compared with noncarrier subjects [9;22]. Decreases 
of VLDL and LDL were observed in pigs treated with avasimibe, an inhibitor of SOAT [60]. 
Consistently, overexpression of human SOAT1 and 2 in rat hepatoma McA-RH7777 cells 
was shown to increase CE synthesis and secretion [59]. Another inhibitor of SOATs, 
pactimibe sulfate, reduced plasma total cholesterol and stabilized atherosclerotic plaques 
in apolipoprotein E-deficient mice [61].  
 
3.5 ANGPTL3 deficiency alters the fatty acid profile of lipoproteins  
Since there is no indication of liver disease in ANGPTL3 LOF carriers [11], it is for ethical 
reasons impossible to obtain liver biopsies from these subjects. We were therefore unable 
to compare the human LOF mutation carriers’ hepatic lipidome to that of the ANGPTL3 KD 
IHH. However, we analyzed in detail their plasma lipoproteins, the composition of which is 












modifications mediated by plasma enzymes and lipid transfer proteins. We consequently 
studied how ANGPTL3 deficiency affects the lipid molecular species profile of lipoproteins, 
and whether any parallels can be found between the profiles of IHH subjected to 
ANGPTL3 KD and lipoproteins of subjects lacking ANGPTL3.  
FA analysis of VLDL, LDL and HDL particles isolated from the plasma of ANGPTL3 LOF 
homozygotes (n=5) and control subjects (n=10) was performed by GC using the same 
approach as for the IHH. Complete FA profiles of the lipoprotein fractions are found in 
Supplementary table 10. When inspecting individual FAs, the most prominent difference 
between the groups was a higher proportion of 18:2n-6 in lipoproteins of the control 
subjects. The effect remained statistically significant in all lipoprotein fractions. In order to 
grasp the changes occurring in all the FAs and not merely in the largest components of the 
profile, we performed a PCA of the entire data using standardized mol% values. A clear 
separation of the groups can be seen in the PCA biplot (Figure 5). PC1 explains 31.7 % of 
the total variation and separates the different fractions (VLDL on the right, LDL in the 
middle and HDL on the left), whereas PC2 explains 21.3 % of the variation and separates 
the control subjects (at the bottom) and the ANGPTL3 LOF homozygotes (at the top). The 
VLDL fractions contained relatively more MUFAs and FAs having <18-carbons, while the 
HDL fractions were enriched in 20-22-carbon PUFAs, >20-24-carbon SFAs or MUFAs 
(ANGPTL3 LOF homozygotes) and saturated dimethyl acetals derived from plasmalogens 
(controls). The right to left change (PC1) in the quality of the FAs is likely affected by the 
activity of LPL, which is higher in ANGPTL3 LOF homozygotes [9]. The efficiency of LPL-
mediated hydrolysis of ester bonds decreases with increasing chain length and 
unsaturation [62;63], and thus relatively short SFAs would be hydrolyzed first, followed by 
MUFAs, leaving the longest PUFAs to be hydrolyzed last. Importantly the FA profile of the 












CETP and PLTP, since no significant differences in their activities were observed between 
homozygous ANGPTL3 LOF variant carriers and control subjects [27]. We think that the 
impact of diet can be ruled out, as the comparison of dietary intakes between ANGPTL3 
LOF subjects and controls did not reveal appreciable differences (data not shown). 
 
3.6 PUFA-containing TAGs are relatively increased in the lipoproteins of ANGPTL3 
LOF homozygotes 
We next analyzed the lipid components of lipoprotein particles derived from ANGPTL3 
LOF homozygotes and control subjects by ESI-MS/MS. The lipoproteins of the ANGPTL3 
LOF homozygotes have been reported to contain less TAG and CEs when compared to 
those of control subjects [9]; Our results are consistent with these findings (fold changes of 
lipids at the class level are listed in Supplementary table 11 and species profiles of each 
class in Supplementary tables 12-16). At the species level the findings in CEs and TAGs 
were, however, opposite to each other. Compared to the controls, the CEs in the 
lipoproteins of ANGPTL3 LOF homozygous subjects included larger proportions of the 
species with 16:1 and 18:1 FAs (Supplementary table 13), whereas in TAGs the relative 
levels of PUFA-containing species were elevated (Figure 6, Supplementary table 12). 
The latter result is likely due to the increased activity of LPL in ANGPTL3 LOF 
homozygotes, since long PUFAs are poor substrates for LPL [62;63], and are thus 
retained. Interestingly, Xu et al. [20] found that knocking down ANGPTL3 in HuH7 cells 
increased the cellular concentration of long-chain TAGs, so it is possible that TAGs in 
VLDL particles of ANGPTL3-deficient subjects could be somewhat enriched in PUFAs 
already as they are secreted. The cellular concentrations of TAGs in the IHH model 












are unable to draw conclusions on the relationship of TAG molecular species composition 
in hepatocytes and plasma lipoproteins. 
CEs are not substrates of LPL, since LPL is a serine-histidine hydrolase and its active site 
favors especially oxyester bond on the glycerol backbone [64-66]. Thus, CEs are not 
affected by the increased activity of LPL but another, unknown mechanism must modify 
their composition in the LOF mutation carriers. One putative explanation for these CE 
species shown in lipoproteins is altered substrate specificity of LCAT.  Most of the CEs in 
human plasma lipoproteins are derived from the function of LCAT [67]. Although LCAT 
displays specificity for the sn-2 position of PC, the composition of the CEs in human 
plasma does not match that of the sn-2 acyl group [68]. We can speculate that ANGPTL3 
deficiency creates changes in FA distribution in PC molecules and therefore LCAT FA 
specificity or the positional specificity in PC [69] is altered and leads to generation of the 
CE species shown in the present study.  
 
 
3.7 ANGPTL3 deficiency changes the quality of SM and its ratio to PC 
The surface monolayer of lipoprotein particles consists mainly of PCs, sphingomyelins 
(SMs) and lysoPCs. We found intriguing changes between ANGPTL3 LOF subjects and 
controls in the species profiles of SM, PC and lysoPC in all the lipoprotein fractions 
(Figure 7A-C, Supplementary tables 14-16). SMs of the lipoproteins obtained from 
ANGPTL3 LOF homozygous subjects contained relatively more of the long SM species, 
especially 24:1 and 24:2, and less of short saturated SMs than the controls. The changes 
in lysoPCs were similar to those seen in TAGs (enrichment of PUFAs) and could be 












FA in the sn-1 position of PC[70]. The study by McLean et al. [70] also indicated that the 
longer the FA in the sn-2 position, the higher activity LPL has against the sn-1 FA, 
resulting in lysoPCs enriched in sn-2 long chain FAs. Moreover, in the lipoproteins of 
ANGPLT3 LOF homozygous subjects there was an enrichment of alkyl ether PCs 
(Supplementary table 16). Since these species are synthesized in peroxisomes [71], the 
finding could imply that the peroxisomes of the LOF subjects are more active. However, to 
our knowledge nothing has been reported on the peroxisomal function in ANGPTL3 LOF 
mutation carriers. Another plausible explanation for the increase of alkyl ether PCs in the 
LOF lipoproteins is that LPL and EL, which are subject to regulation by ANGPTL3, are only 
hydrolyzing ester and not ether bonds [64;65;72]. Thereby, the elevated phopholipase 
activity of these enzymes in LOF subjects could result in a relative enrichment of non-
substrate ether phospholipid species.  
The SM/PC ratio was increased in all lipoprotein fractions derived from ANGPTL3 LOF 
homozygous subjects when compared to controls (Figure 7A). This could result from 
several different mechanisms. We did not see changes in the SM/PC ratio in the IHH cell 
model (data not shown). However, this does not rule out the possibility that nascent VLDLs 
may be enriched in SM; Once entering general circulation these particles could be rapidly 
lipolyzed by LPL, and the extra surface SM together with some PCs could be transported 
by PLTP to HDL and LDL, therefore increasing the proportion of SM in these particles. 
Indeed, it has been shown that SM is very efficiently transferred by PLTP [73].  
The enrichment of SMs in lipoproteins obtained from ANGPTL3 LOF homozygotes is 
highly interesting in the light of the study of Ruuth et al. [74], where the saturated SM 
species and SM 16:1 were associated with LDL aggregation, which increases the risk of 
cardiovascular death. Thus, even though the SM/PC ratio is increased in the LDL of 












these subjects could make their LDL less prone to aggregation as  compared to controls. It 
should also be noted that in HDLs an increased SM/PC ratio leads to an increased ability 
to receive cholesterol from cells, improving the cardioprotective capacity of the lipoprotein 
[75]. On the other hand, we have to consider that enrichment of HDL with SM inhibits 
cholesterol esterification, and this inhibition can be reversed by the degradation of SM, 
which demonstrates that SM is a physiological inhibitor of cholesterol esterification in 
circulation and competes with the PC acyl donor on the surface of HDL particle [76]. This 
would attenuate reverse cholesterol transport process which needs LCAT facilitated step 
of free cholesterol esterification. When interpreting the above data, one should also keep 
in mind that the absolute amounts of cholesterol and TAGs in the lipoproteins of ANGPTL3 
deficient subjects are strongly reduced, which is by itself beneficial for the cardiovascular 
health of these individuals. 
 
CONCLUSIONS 
Loss-of-function mutations in ANGPTL3, an inhibitor of lipoprotein lipase (LPL), cause a 
drastic reduction of all major serum lipoproteins and are protective against the 
development of atherosclerotic CVD. Therefore, ANGPTL3 is emerging as a therapy 
target; Clinical trials with agents targeting ANGPTL3 have already reached phase 3. 
Although ANGPTL3 is produced almost exclusively by the liver, there is no data on its 
function in determining the hepatocellular gene expression patterns and lipidome. In the 
present study we characterized the impacts of ANGPTL3 depletion on the hepatocyte 
(IHH) transcriptome and lipidome and whether there are parallels between the lipidomes of 
ANGPTL3-deficient hepatocytes and of plasma VLDL, LDL, and HDL isolated from 













IHH depleted of ANGPTL3 displayed distinct changes in total FA composition and in the 
molecular species composition of several lipid classes, characterized by an increase in the 
mol% of n-6 and n-3 polyunsaturated FAs (PUFAs). The VLDL, LDL and HDL of the 
ANGPTL3 LOF subjects showed a significant drop of 18:2n-6, while several 
polyunsaturated TAG species were enriched, most likely due to elevated activity of LPL 
which prefers saturated and shorter chain FAs esterified to the glycerol backbone [62;63]. 
The LOF subjects’ lipoproteins displayed an increased SM/PC molar ratio and enrichment 
of 24:1 and 24:2 SM species. Since the SM/PC ratio is increased in all lipoprotein fractions 
of t LOF subjects, it cardiometabolic implications are contr versial. Similar to the IHH, 
increased mol% of PUFAs was found in LysoPCs, which could result from increased PLA1 
activity of LPL [70]. 
 
Cholesterol esters were markedly reduced in the ANGPTL3 KD hepatocytes, coinciding 
with suppression of SOAT1/ACAT1. However, we did not see any change in the 
expression of SOAT2, which is the major isoform in human liver in vivo [77]. Previously, 
we have also detected a low CE/apoB100 molar ratio in the ANGPTL3 LOF homozygote 
subjects [9] as well as reduced CEs in VLDL remnants of these subjects [22]. However, 
the putative causality between the cultured hepatocyte and in vivo observations requires 
further investigation.  
 
The PUFA increase in the ANGPTL3-depleted IHH coincided with an elevation of PUFA-
derived lipid mediators. Among these there were several mediators with documented 
functions in resolution of inflammation, protection from lipotoxic and hypoxia-induced ER 
stress, hepatic steatosis and insulin resistance [52;53] or in mediating the recovery from 












crucial physiological mechanism affecting atherogenesis [78-80]. Consistent with the lipid 
mediator data, altered expression of several KEGG pathways related to fatty acid 
metabolism was observed. The impact of ANGPTL3 inhibition on synthesis of the PUFA-
derived mediators deserves further investigation; when fresh plasma becomes available 
from the ANGPTL3 LOF carriers, it will be extremely interesting to study the lipid mediators 
in these subjects. 
 
To conclude, the present work reveals distinct impacts of ANGPTL3 depletion on the 
hepatocellular lipidome, transcriptome and lipid mediators, as well as on the lipidome of 
lipoproteins isolated from the plasma of ANGPTL3-deficient human subjects. This 
lipidomic/transcriptomic data is important to consider when targeting ANGPTL3 for therapy 
and translating it to the human context. 
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Table 1. Several KEGG pathways related to lipid metabolism are altered in ANGPLT3 knock-down 
hepatocytes. A total of 171 pathways were obtained in the KEGG pathway enrichment analysis, 




Pathway p value Adjusted  
p value 
1 Inositol phosphate metabolism 2.329E-25 7.196E-23 
2 Phosphatidylinositol signaling system 1.581E-23 2.442E-21 
3 Fatty acid metabolism 1.198E-22 1.234E-20 
4 Glycerophospholipid metabolism 1.172E-19 9.055E-18 
6 AMPK signaling pathway 3.653E-18 1.881E-16 
7 Biosynthesis of unsaturated fatty acids 1.133E-17 5.002E-16 
10 Phospholipase D signaling pathway 2.606E-16 8.053E-15 
13 PPAR signaling pathway 6.831E-16 1.624E-14 
14 Sphingolipid signaling pathway 1.780E-15 3.929E-14 
17 Sphingolipid metabolism 1.107E-14 2.012E-13 
19 Fatty acid elongation 2.556E-13 4.157E-12 
29 Peroxisome 1.579E-10 1.683E-09 
31 Cholesterol metabolism 4.352E-10 4.338E-09 
44 Ether lipid metabolism 2.027E-08 1.423E-07 
45 Fatty acid degradation 2.497E-08 1.715E-07 
48 Glycerolipid metabolism 8.699E-08 5.600E-07 
90 Steroid biosynthesis 1.397E-05 4.795E-05 
112 ABC transporters 3.483E-04 9.608E-04 
113 Fatty acid biosynthesis 3.866E-04 1.057E-03 



























Figure 1. ANGPTL3 knock-down efficiency in immortalized human hepatocytes. (A) ANGPTL3 
mRNA expression of IHH cells treated with non-targeting shRNA (control) and shRNA targeting 
ANGPTL3 (shANGPTL3). The values represent mean ± SD, n=3. (B) ANGPTL3 protein levels in 
control and ANGPTL3 knock-down cells (data represent mean fold change ± SD, n=3). (C) 
Representative western blot image of ANGPTL3 expression in control and knock-down cells with 
corresponding total protein. *** p<0.001, * p<0.05.  
Figure 2. MUFAs are decreased and PUFAs increased in ANGPTL3 knock-down cells. (A) Sums 
of saturated and unsaturated fatty acids determined by gas chromatography. The values represent 
mean ± SD, n=6. ** p< 0.01, *** p<0.001. (B) PCA of individual FA species. The samples located 
furthest from the origin of the PCA biplot (marked as +) on one side contain relatively more of the 
lipid species furthest on that same side. The longer the distance between two samples on the plot 
the more their lipid profiles differ from each other. The percentages represent the proportion of the 
variation in the data each principal component axis explains. Ctrl=control cells treated with non-
targeting RNA, shANGPTL3/ShA3=cells treated with shRNA against ANGTPL3. 
Figure 3. Knocking down ANGPTL3 enhances the production of lipid mediators. (A) PLS-DA 
analysis of lipid mediator concentrations. The score plot shows clear separation between the 
control (red dots) and knock-down (shANGPTL3; green dots) samples. Coloured spherical areas 
display the 95% confidence region. (B) VIP scores of lipid mediator variables that contribute most 
to the separation in the PLS-DA model. All of these mediators are more abundant in the ANGPTL3 
knock-down (shA3) cells as indicated by the colour scale. RvD6=resolvin D6, PGD2=prostaglandin 
D2, TxB2=thromboxane B2, HDPA=hydroxydocosapentaenoic acid, MaR=maresin, LXA4=lipoxin A4, 
LTB4=leukotriene B4,  HDHA=hydroxydocosahexaenoic acid, HETE=hydroxyeicosatetraenoic acid. 
Figure 4. Cholesterol ester synthesis and SOAT1 expression are reduced in ANGPTL3 cells. (A) 
Total cholesterol esters (CE) in control and ANGPTL3 knock-down cells (data represent mean ± 












n= 6) (C) representative Western blot of SOAT1 in control and ANGPTL3 knock-down cells (D) 
Quantification of protein expression of SOAT1 in ANGPTL3 knock-down and control cells (mean ± 
SD, n=4). (E) [3H]acetic acid labeled CE in control and ANGPTL3 knock-down cells (mean ± SD, 
n=12). (F) [3H]oleic acid incorporation into CE in control and ANGPTL3 knock-down cells (mean ± 
SD, n=18). *** p<0.001, ** p<0.001.  
Figure 5. ANGPTL3 LOF carriers have altered lipoprotein fatty acid profiles. PCA of the lipoprotein 
fatty acid profiles of control and ANGPTL3 LOF subjects. Lipoprotein fractions were isolated from 
the plasma of ANGPTL3 LOF homozygote and control subjects by sequential density 
ultracentrifugation and fatty acids were analyzed by gas chromatography. Sample markings: 
Group+Fraction; C=control, HZ=ANGPTL3 LOF homozyg te, V=VLDL, L=LDL, H=HDL. 
DMA=dimethylacetal. 
Figure 6. PUFAs accumulate in TAGs of lipoproteins derived from ANGPTL3 LOF homozygotes. 
TAG of lipoproteins from ANGPTL3 loss-of-function and control subjects was analyzed by ESI-
MS/MS. Bar graphs are shown for VLDL (upper panel) and LDL (lower panel) fractions, but also in 
HDL the effect was clear and very similar to that seen in LDL (Supplementary table 12). The values 
represent mean ± SD, n=4-10. * p<0.05, ** p< 0.01, *** p<0.001. 
Figure 7. ANGPTL3 deficiency alters the surface lipids of lipoprotein particles. (A) SM/PC ratio of 
different lipoprotein fractions. ANGPTL3=ANGPTL3 LOF homozygote. (B) PCA of the relative 
profile of SM in LDL. C=control, HZ=ANGPTL3 LOF homozygote. All species have a sphingosine 
18:1 backbone, except SM 24:2 is likely a mixture of 18:1/24:2 and 18:2/24:1. (C) LysoPC species 
profile of LDL derived from control subjects and ANGPTL3 LOF homozygotes. The values 
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